N
Neuraptive Therapeutics
Bringing novel therapeutic technology for the acute surgical repair of injured peripheral nerves
About Neuraptive Therapeutics
Neuraptive Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for peripheral nerve injuries. The company operates in the pharmaceutical and medical device market, targeting healthcare providers and patients who suffer from nerve damage. Neuraptive's business model revolves around research and development (R&D) of novel treatments, which are then brought to market through clinical trials and regulatory approvals. Revenue is generated through the commercialization of these therapies, including sales and potential licensing agreements. The company leverages its experienced leadership team, with extensive backgrounds in biotech and pharmaceutical industries, to navigate the complex landscape of drug development and regulatory compliance. Neuraptive is headquartered in Philadelphia, with additional operations in Colorado.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Oct 2022 | $38M | $153M | Undisclosed | ↗ |
| SERIES AOther financing | Dec 2018 | $12M | $46M | New Rhein Healthcare | ↗ |
Growth signals
Latest recorded traffic for Neuraptive Therapeutics is 2K monthly website visits, up 17.6% over the last three months. Neuraptive Therapeutics's team declined 13.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Neuraptive Therapeutics in the Tredyffrin Township ecosystem
The Neuraptive Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Central Texas Angel Network
New Rhein Healthcare
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Neuraptive Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neuraptive Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









